omniture
logo
Search
TESSA THERAPEUTICS LTD
Media Room

Latest News

rss

Tessa Therapeutics Announces Enrollment of 12 Patient Pilot Cohort in its Relapsed or Refractory Hodgkin Lymphoma Phase 2 Study

82 Patient Pivotal cohort expected to commence in second half of 2021 BEDMINSTER, N.J. and SINGAPOR...

2021-04-30 18:00 1777

Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a cl...

2021-02-10 19:51 1834

Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a cl...

2021-02-10 19:12 1648

Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy

BEDMINSTER, N.J. and SINGAPORE, Jan. 18, 2021 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinica...

2021-01-18 19:00 1626

Tessa Therapeutics Appoints David McIntyre as Chief Financial Officer

BEDMINSTER, N.J. and SINGAPORE, Dec. 17, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinica...

2020-12-17 22:32 2554

Tessa Therapeutics Announces Results from Two Independent Phase 1/2 Trials of Autologous CD30 CAR-T Cell Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma

SINGAPORE, Aug. 6, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy c...

2020-08-06 19:00 2885

Tessa Therapeutics Announces New Executive Leadership

SINGAPORE, May 5, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy co...

2020-05-05 00:00 2131

Tessa Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to its CD30 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory CD30-positive Classical Hodgkin Lymphoma

SINGAPORE, Feb. 27, 2020 /PRNewswire/ -- Tessa Therapeutics (Tessa), a clinical-stage cell therapy ...

2020-02-27 20:00 2017

Tessa Therapeutics to Open 90,000 Square Foot Commercial-Scale Cell Therapy Manufacturing Facility in Singapore in 2020

* State-of-the-art manufacturing facility will support clinical and commercial production of cell...

2019-12-19 20:00 1131

Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer

* The partnership will leverage Tessa Therapeutics' global operational capabilities and cell ther...

2019-06-13 07:15 2331

Tessa Therapeutics, in Collaboration with Baylor College of Medicine, Presents Preclinical Results Showing Enhanced T Cell Responses Against HER2-Positive Solid Tumors Using Novel Combination CAR T Cell Therapy

* Preclinical, 'proof-of-concept' results for a novel 'all-in-one' immunotherapy for the treatmen...

2019-04-30 22:00 2375